 This study will be conducted as a standard Phase 1b, open-label, multi-center study of patients with relapsed andor refractory Myeloma who have received at least two prior therapeutic treatments or regimens. Throughout the Phase I portion of this study, a standard 33 dose escalation design will be utilized. Two dosing cohorts will evaluate escalating doses SAR650984 5mgkg and 10 mgkg Day 1 and 15 of each 28-day cycle with standard dose Carfilzomib 20-27 mgmg2. Once a safe dose is established, an expansion cohort will further evaluate safety and begin to assess activity of this combination SAR650984 5mgkg or 10 mgkg Day 1 and 15 of each 28-day cycle with standard dose Carfilzomib. 